Sales of DORYX increased $4.5 million, or 16.4%, in the quarter ended December 31, 2007, compared with the prior year quarter due to increased demand and ...
Sales of DORYX increased $4.5 million, or 16.4%, in the quarter ended December 31, 2007, compared with the prior year quarter due to increased demand and ...
2/29/2008 7:59:16 AM Warner Chilcott Limited (WCRX), a specialty pharmaceutical company, on Friday announced earnings for the fourth quarter of fiscal 2007, ...
Sales of DORYX increased $4.5 million, or 16.4%, in the quarter ended December 31, 2007, compared with the prior year quarter due to increased demand and ...
Warner projects 2008 revenue of $935 million to $945 million, primarily driven by oral contraceptive Loestrin 24 FE, acne drug Doryx, oral contraceptive ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth largely driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...
Warner projects 2008 revenue of $935 million to $945 million, primarily driven by oral contraceptive Loestrin 24 FE, acne drug Doryx, oral contraceptive ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth largely driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...